Search clinical trials for: once a day

Total 496316 results

Veloxis Pharmaceuticals
CTI Clinical Trial and Consulting Services; Aptuit

Completed

Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients

Liver Failure

United States
AstraZeneca
Eli Lilly and Company

Completed

Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

Type 2 Diabetes Mellitus

United States, Czech Republic, France, Korea, Republic of, Russian Federation, Spain, Mexico, Australia, Belgium, Denmark, Germany, Hungary, Netherlands, Puerto Rico, Greece, Taiwan
Lundquist Institute for Biomedical Innovation at...
Abbott Nutrition; DaVita Dialysis

Completed

Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients (AIONID)

Inflammation | Oxidative Stress | Hypoalbuminemia | Protein-energy Malnutrition | Chronic Kidney Disease (CKD) Hemodialysis

United States
Veloxis Pharmaceuticals
CTI Clinical Trial and Consulting Services; Aptuit

Completed

Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients

Renal Failure | Kidney Failure

United States
Bayer
Janssen Research & Development, LLC

Completed

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion (X-VERT)

Atrial Fibrillation

Belgium, France, Spain, China, Italy, United States, Canada, South Africa, Portugal, Singapore, Germany, Greece, Netherlands, United Kingdom, Brazil, Denmark, Finland
AstraZeneca
Eli Lilly and Company

Completed

A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)

Type 2 Diabetes Mellitus

United States, Mexico, India
Genzyme, a Sanofi Company

Completed

Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing

Chronic Kidney Disease

United States
Bristol-Myers Squibb

Completed

Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients (SPARTAN)

HIV, Combination Therapy

France, Germany, Spain, United States, Italy, Poland, United Kingdom
Hospital Universitario Central de Asturias
Sanofi

Terminated

Basal-bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes (PININ Study) (PININ)

Type 2 Diabetes Mellitus
SK Life Science, Inc.

Completed

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

United States
Synta Pharmaceuticals Corp.

Completed

Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors

Solid Tumors

United States
LEO Pharma

Completed

Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm

Actinic Keratosis

Australia
Boehringer Ingelheim

Completed

Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

United States
Ministry of Health, Rwanda

Completed

An Open Label, Blinded Assessor, Trial Comparing Odor Levels Due to Different Hygiene Methods With PrePexTM (RMC-10)

Odor Levels of Study Arms

Rwanda
Boehringer Ingelheim

Completed

An Observational Cohort Study to Evaluate the Safety and Efficacy of Micardis Tablets Taken Once Daily at 40 mg/Day and 80 mg/Day in Hypertensive Patients Under Real Life Conditions in Usual Clinical Practice

Hypertension
PENTA Foundation

Completed

PENTA15: Pharmacokinetic Study of Once Versus Twice Daily Abacavir in HIV-1 Infected Children Aged 3 to <36 Months (PENTA15)

HIV Infection

France, Germany, Italy, Spain, United Kingdom
Gilead Sciences

Completed

Safety Study of Once a Day ART and Opiate Substitute. (3OD)

HIV Infections

Germany
The University of Texas Health Science Center,...

Completed

"The Once A Day Protease Inhibitor Regimens"

HIV Infections

United States
University of Cincinnati
Patty Brisben Foundation For Women's Sexual Health

Unknown

Trigger Point Injections and Pelvic Rehabilitation for the Treatment of Pelvic Floor Myalgia and Sexual Pain

Dyspareunia

United States
University of Florida
Sanofi

Completed

Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia

Type 1 Diabetes

United States
St Stephens Aids Trust

Completed

Pharmacokinetics of Tenofovir and Tenofovir-diphosphate, Emtricitabine and Emtricitabine-triphosphate, and Rilpivirine Once Daily Over 14 Days Following Drug Intake Cessation in Healthy Volunteers

HIV

United Kingdom
Dong-A Pharmaceutical Co., Ltd.

Completed

Safety Study of Once-a-Day Dosing of Udenafil to Treat Erectile Dysfunction

Erectile Dysfunction
University of Pavia
IRCCS Policlinico S. Matteo

Unknown

Triple Therapy in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Italy
AbbVie (prior sponsor, Abbott)
Triaca Magna, SA

Completed

Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets) (QD-Kapital)

Human Immunodeficiency Virus Infection

Spain
Warner Chilcott

Completed

A Comparison of Once a Day Dose Compared to 2 Doses/Day

Ulcerative Colitis

United States, Canada, Puerto Rico
Xijing Hospital

Completed

Mildronate for Acute Ischemic Stroke

Acute Ischemic Stroke

China
LEO Pharma

Completed

Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis

Actinic Keratosis

Australia
Galapagos NV

Completed

Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy Subjects

Healthy

Belgium
Cardiovascular Clinical Studies
GlaxoSmithKline

Completed

Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-daily or Twice-daily Coreg

Chronic Heart Failure

United States
Watson Pharmaceuticals

Completed

Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems

Hypogonadism

United States
Janssen-Cilag International NV

Completed

Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir (MONET)

HIV Infections | Human Immunodeficiency Virus | Acquired Immunodeficiency Syndrome Virus | AIDS Virus

United Kingdom, Belgium, Germany, Spain, Portugal, Israel, Denmark, Russian Federation, Austria, Hungary, Switzerland
Azad University of Medical Sciences

Completed

Effect of Fluoride Varnish and CPP-ACP on Oral and Salivary Symptoms During Chemotherapy

Mucositis | Infection | Dry Mouth

Iran, Islamic Republic of
University of Washington
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

CEP-1 Hormonal Regulation of Circulating Endothelial Progenitor Cells and HDL-C in Men (CEP-1)

Healthy
The University of Texas Medical Branch, Galveston

Completed

Cycled Testosterone Replacement Study

Hypogonadism

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics of Certoparin in Subjects With Renal Insufficiency and Healthy Subjects

Renal Insufficiency

Hungary
University of Milan
Chiesi Farmaceutici S.p.A.

Completed

Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis

Cystic Fibrosis

Italy
ViiV Healthcare
GlaxoSmithKline

Completed

HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults

HIV-1 Infection | Infection, Human Immunodeficiency Virus I

Germany, Spain, France, Belgium, United Kingdom, Italy, Romania, Russian Federation, Switzerland
GlaxoSmithKline

Completed

Open-label Comparison of 24hr Gastric pH on Days 1, 2, 7 With Once-daily Administration of Lavoltidine 40 mg.

Reflux, Gastroesophageal | Gastroesophageal Reflux Disease

Australia
AstraZeneca
Bristol-Myers Squibb

Completed

A Study to to Assess the Effect of Dapagliflozin When Administered Once a Day Versus Twice a Day on Blood Glucose

Healthy Volunteers

Germany
Novartis

Completed

Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States, Spain, Turkey, France, Netherlands, Germany
Labopharm Inc.

Completed

A Four-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol Once a Day 100, 200 and 300 mg Versus Placebo for the Treatment of Pain Due to Osteoarthritis of the Knee (With 7-Day Follow-up)

Pain
Labopharm Inc.

Completed

An Open-Label Long-term Safety Study of Tramadol HCl OAD (Once A Day) 300 mg in the Treatment of Pain Due to Osteoarthritis of the Knee

Osteoarthritis, Knee
Labopharm Inc.

Completed

A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol HCl Once-a-Day Versus Placebo for the Treatment of Pain Due to Osteoarthritis

Pain | Osteoarthritis
Labopharm Inc.

Completed

A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol HCl / Contramid® Tablets to Twice Daily Tramadol HCl (SR) for the Treatment of Osteoarthritis of the Knee

Pain | Osteoarthritis, Knee
Labopharm Inc.

Completed

A Four-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol Once a Day 100, 200 and 300 mg Versus Placebo for the Treatment of Pain Due to Osteoarthritis of the Knee

Pain | Osteoarthritis, Knee
Labopharm Inc.

Completed

A Pharmacodynamic/Pharmacokinetic Study to Determine the Onset of Analgesic Effect and Plasma Levels of Tramadol in Patients With Acute Low Back Pain Receiving a Single 200 mg Dose of Tramadol Contramid® Once-a-Day

Acute Low Back Pain
Labopharm Inc.

Completed

Comparative Bioavailability Between Two Tramadol Formulations: Study of the Better Controlled Release of a New 200 mg Once A Day (OAD) Formulation Versus Zytram® 200 mg

Pain
Novartis

Completed

Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients

Acute Gout

United States, Russian Federation, Switzerland, Germany, Turkey, Poland, Argentina, Canada, Belgium, France, United Kingdom
Nagaoka Red Cross Hospital

Unknown

Effect of DPP-IV Inhibitor on Glycemic Control and Autonomic Neuropathy in Adult Patients With Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Radboud University Medical Center

Completed

Nijmegen Antihypertensive Management Improvement Study (NAMIS)

Primary Hypertension

Netherlands

3

Subscribe